Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses
暂无分享,去创建一个
Ji-Kyung Choi | B. Jenkins | Ji-Kyung Choi | Jiaqiang Ren | Haibo Xu | Y. I. Chen | Bruce G Jenkins | Jiaqian Ren | Y Iris Chen | Haibo Xu | Ji-Kyung Choi
[1] B. Rosen,et al. Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects , 1988, Magnetic resonance in medicine.
[2] B. Rosen,et al. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging , 2005, Psychopharmacology.
[3] A. Blamire,et al. Region‐specific effects of a tyrosine‐free amino acid mixture on amphetamine‐induced changes in BOLD fMRI signal in the rat brain , 2007, Synapse.
[4] B. MacVicar,et al. Calcium transients in astrocyte endfeet cause cerebrovascular constrictions , 2004, Nature.
[5] Ji-Kyung Choi,et al. Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling , 2006, NeuroImage.
[6] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[7] B. Jenkins,et al. Mapping Dopamine Function in Primates Using Pharmacologic Magnetic Resonance Imaging , 2004, The Journal of Neuroscience.
[8] S. Strakowski,et al. D3 dopamine receptor, behavioral sensitization, and psychosis , 2001, Neuroscience & Biobehavioral Reviews.
[9] Angelo Bifone,et al. In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI , 2007, NeuroImage.
[10] A. L. Dixon,et al. Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI , 2005, Neuropharmacology.
[11] J. Mandeville,et al. Vascular filters of functional MRI: Spatial localization using BOLD and CBV contrast , 1999, Magnetic resonance in medicine.
[12] T. Takano,et al. Signaling at the Gliovascular Interface , 2003, The Journal of Neuroscience.
[13] Ji-Kyung Choi,et al. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. , 2007, Journal of medicinal chemistry.
[14] D. Clark,et al. Effects of low, autoreceptor selective doses of dopamine agonists on the discriminative cue and locomotor hyperactivity produced by d-amphetamine , 2005, Journal of Neural Transmission / General Section JNT.
[15] K. Chergui,et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. , 1997, The Journal of pharmacology and experimental therapeutics.
[16] R. Wightman,et al. Real‐Time Monitoring of Electrically Stimulated Norepinephrine Release in Rat Thalamus: II. Modeling of Release and Reuptake Characteristics of Stimulated Norepinephrine Overflow , 1993, Journal of neurochemistry.
[17] J. Bergman,et al. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.
[18] D. Cory-Slechta,et al. Apparent mediation of the stimulus properties of a low dose of quinpirole by dopaminergic autoreceptors. , 1993, The Journal of pharmacology and experimental therapeutics.
[19] Bruce G. Jenkins,et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[20] P. Garris,et al. Heterogeneity of evoked dopamine overflow wihin the striatal and striatoamygdaloid regions , 1994, Neuroscience.
[21] P. Garris,et al. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[22] R. Neubig,et al. Regulators of G protein signaling & drugs of abuse. , 2005, Molecular interventions.
[23] J. Mandeville,et al. Improved mapping of pharmacologically induced neuronal activation using the IRON technique with superparamagnetic blood pool agents , 2001, Journal of magnetic resonance imaging : JMRI.
[24] B R Rosen,et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data , 1997, Magnetic resonance in medicine.
[25] B. Rosen,et al. Regional sensitivity and coupling of BOLD and CBV changes during stimulation of rat brain , 2001, Magnetic resonance in medicine.
[26] M. Martres,et al. The third dopamine receptor (D3) as a novel target for antipsychotics. , 1992, Biochemical pharmacology.
[27] P. Greengard. The neurobiology of slow synaptic transmission. , 2001, Science.
[28] P. Goldman-Rakic,et al. Dopaminergic regulation of cerebral cortical microcirculation , 1998, Nature Neuroscience.
[29] D. Cory-Slechta,et al. Functional alterations in dopamine systems assessed using drug discrimination procedures. , 1993, Neurotoxicology.
[30] S. Laughlin,et al. An Energy Budget for Signaling in the Grey Matter of the Brain , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] B R Rosen,et al. Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. , 1999, Neuroreport.
[32] R Weissleder,et al. Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties , 1993, Magnetic resonance in medicine.
[33] M. C. Angulo,et al. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation , 2003, Nature Neuroscience.
[34] G. Crelier,et al. Linear coupling between cerebral blood flow and oxygen consumption in activated human cortex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[35] Z. Kruk,et al. Regional differences in evoked dopamine efflux in brain slices of rat anterior and posterior caudate putamen , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.
[36] Ji-Kyung Choi,et al. Exogenous contrast agent improves sensitivity of gradient‐echo functional magnetic resonance imaging at 9.4 T , 2004, Magnetic resonance in medicine.
[37] M. Galloway,et al. Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. , 1995, The Journal of pharmacology and experimental therapeutics.
[38] J. Mcculloch,et al. Vasomotor responses of cerebral arterioles in situ to putative dopamine receptor agonists , 1985, British journal of pharmacology.